Roche Hedges On U.S. Launch Of Mircera With November FDA Action Date Expected
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision in Amgen’s patent infringement case against Roche over the continuous erythropoiesis receptor activator is expected in October.
You may also be interested in...
Despite FDA Approval, Near Term U.S. Mircera Launch Appears Doubtful
Amgen has legal hold on the commercialization of Roche’s long-acting erythropoiesis stimulating agent for now.
Despite FDA Approval, Near Term U.S. Mircera Launch Appears Doubtful
Amgen has legal hold on the commercialization of Roche’s long-acting erythropoiesis stimulating agent for now.
Amgen EPO Patent Win Over Roche Could Derail Mircera Launch
Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.